Skip to main content
. 2022 Nov 1;13:995791. doi: 10.3389/fimmu.2022.995791

Table 1.

Clinical and laboratory data of NEC infants and control volunteers (n=8).

Groups NEC groups (N1-N4) Control group (C1-C4)
Infants N1 N2 N3 N4 C1 C2 C3 C4
Gestational Age (w+d) 32+2 28+3 25+6 27+2 38 39 29+1 26+1
Birth weight (g) 1380 1260 990 1200 3100 3990 980 740
Age of onset of NEC (d) 29 28 50 37 10 51
Delivery mode Caesarean section Caesarean section Caesarean section Vaginal delivery Vaginal delivery Vaginal delivery Caesarean section Caesarean section
Hs-CRP* in acute phase of NEC (mg/L) 69.48 10.83 67.85 88.56 1.37 1.13 59.88 94.31
Clinical diagnosis Acute stage of NEC Acute stage of NEC Acute stage of NEC Acute stage of NEC Congenital anal atresia Congenital jejunal atresia Recovery stage of NEC Recovery stage of NEC
Surgical pathologic staging NEC III NEC IIb (multifocal lesions) NEC IIIa NEC IIIa
Complication RDS*, PDA*, Neonatal cholestasis, Sepsis, Short bowel syndrome RDS*, BPD*, PDA*, Sepsis, Neonatal cholestasis, Intraventricular hemorrhage RDS*, BPD*, PDA*, ROP*, Sepsis, Neonatal cholestasis RDS*, PDA*, infantile hepatitis syndrome RDS*, Sepsis RDS*, BPD*, PDA*, Sepsis, ROP*, infantile hepatitis syndrome

*hs-CRP: hypersensitive C-reactive protein, RDS: Respiratory distress syndrome, BPD: Bronchopulmonary Dysplasia, ROP: Retinopathy of Prematurity, PDA: Patent ductus arteriosus. The normal range of hs-CRP is less than 8 mg/L. N1-4 stand for patients in NEC group, C1-4 stand for patients in control group.